Ceeta

Quick links to important sections

Ceeta

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceeta

Quick Facts

Property Description
Active Ingredients Ceftriaxone, Sulbactam
Pharmaceutical Form Sterile Powder for Injection
Pharmacological Class Combination Antibiotic, beta-Lactam Agent
Origin Semi-synthetic and Synthetic
Route of Administration Parenteral (Injection)

What is Ceeta and What Pharmacological Class Does it Belong To?

Ceeta is a prescription-only medicine classified as a Fixed-Dose Combination (FDC) antibacterial agent. It contains two active components: Ceftriaxone, which is a third-generation cephalosporin antibiotic, and Sulbactam, which is an enzymatic inhibitor. This two-drug pairing is supported by pharmacological studies for its ability to manage complicated infections and is often used in hospital settings. The cephalosporin class of antibiotics is widely recognized for its broad spectrum of activity against various bacteria.

Composition and Form: Why Does Ceeta Contain Two Active Ingredients?

The composition of Ceeta is engineered for synergistic bactericidal activity. While Ceftriaxone provides the primary germ-killing action by inhibiting bacterial cell wall production, Sulbactam protects it. Sulbactam acts as a beta-Lactamase inhibitor by neutralizing the bacterial enzymes that degrade the antibiotic, thereby sustaining the effectiveness of Ceftriaxone. This mechanism is clinically recognized for improving activity against strains that have developed resistance to single-agent treatments. The drug is supplied as a sterile powder for injection, necessitating the parenteral route for its administration.

General Therapeutic Purpose

The fundamental purpose of Ceeta is to provide a robust, broad-spectrum intervention for fighting systemic bacterial infections throughout the body. The FDC design aims to counteract common bacterial defense mechanisms, enhancing the reliability of the treatment. Delivered via injection, the drug's goal is to achieve rapid, effective concentrations required for high-grade systemic antimicrobial therapy.

Regulatory References

  1. Cephalosporins - StatPearls - NCBI Bookshelf

What side effects are possible with Ceeta?

Possible Side Effects and Safety Information

The safety profile of Ceeta (Ceftriaxone and Sulbactam) is structured around official regulatory classifications of adverse reactions, grouping them by frequency and the body system affected, according to labeling provided by government health authorities.

Frequency-Classified Adverse Reactions

The most frequently reported effects, classified as Common (ge 1/100 to < 1/10), often involve the blood and lymphatic system (e.g., eosinophilia, leukopenia, thrombocytopenia) and the gastrointestinal system (diarrhea). Transient elevation of hepatic enzymes (AST/ALT) and skin rash are also typically classified as Common. Uncommon reactions (ge 1/1000 to < 1/100) include headache, dizziness, itching (pruritus), and discomfort at the injection site.

System-Organ-Class (SOC) Focus

Adverse events are formally reported across several System-Organ Classes (SOCs). Significant SOCs include Gastrointestinal Disorders, Hepatobiliary Disorders, Blood and Lymphatic System Disorders, and Immune System Disorders. Effects on the Renal and Urinary system, such as hematuria or transient changes in serum creatinine, are documented, often classified as Rare or Frequency Not Known.

Serious Adverse Reactions and Safety Constraints

Official labeling documents severe, though rare, adverse reactions. These include Anaphylaxis and other severe hypersensitivity reactions, Serious Cutaneous Adverse Reactions (e.g., Stevens-Johnson Syndrome), and Immune-Mediated Hemolytic Anemia. A specific and mandatory constraint is the contraindication for administering the drug simultaneously with any calcium-containing intravenous solution due to the risk of potentially fatal precipitation, particularly in neonates. Furthermore, the drug is officially contraindicated in hyperbilirubinemic neonates and requires close monitoring for patients with severe combined hepatic and renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Domain Official Regulatory Statements
Documented Overdose Presentations Acute presentations may include nausea, vomiting, and diarrhoea, as reported in official labeling. Accumulation or overdosage carries the potential for severe systemic toxicity.
Physiological Systems Affected Severe effects are documented across the Central Nervous System (CNS), Renal/Urinary, and Biliary/Hepatic systems.
Dose-Related or Exposure-Related Factors High doses are associated with an increased risk of precipitation in the urinary tract. Drug accumulation occurs in patients with impaired clearance, such as those with combined hepatic and significant renal dysfunction.
Population-Specific Overdose Notes The risk of precipitation (urolithiasis) is elevated in children treated with high daily doses. Close monitoring of serum concentrations is required in patients with compromised hepatic and renal function.
Emergency-Response Statements In the event of acute overdosage, supportive and symptomatic treatment must be initiated. Treatment is solely symptomatic.
When Immediate Medical Help is Required Immediate medical attention is necessary to address the risk of severe complications, which include seizures, encephalopathy, postrenal acute renal failure, and painful gallbladder precipitation.

Overdose Classifications (High-Level)

Classification Official Regulatory Statements
Severity Classification Overdosage carries the risk of severe complications, including serious neurological adverse reactions and acute renal failure, according to regulatory documents.
Overdose-Context Constraints No specific antidote is known for this overdosage. Furthermore, the active component is not effectively removed by haemodialysis or peritoneal dialysis procedures.

Resulting Overdose Structure

Official regulatory information describes overdose manifestations that range from acute gastrointestinal upset to life-threatening complications, especially those affecting the CNS and renal function. The primary constraint in overdose management is the lack of a specific antidote and the inability to reduce drug concentration via dialysis. This necessitates prompt medical consultation to ensure symptomatic and supportive treatment is initiated and to monitor for accumulation-related toxicities, particularly in vulnerable populations.

Therapeutic Uses of Ceeta

What Ceeta Treats: Main Uses and Benefits

Ceeta is a medication generally used to manage the symptoms related to conditions involving susceptible bacteria. It is commonly used to help with infections in the respiratory tract, the urinary tract, and skin and soft tissue. This supportive approach contributes to easing the overall symptom load and helps in the management of acute episodes.


Symptom Relief and Functional Support

Ceeta is relevant in contexts marked by increased discomfort or tension, addressing symptoms linked to bacterial processes that may appear suddenly or fluctuate. It is applied when symptoms create noticeable functional strain, such as a fever related to systemic imbalance or localized discomfort like painful urination or a severe cough. This medication helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability and supporting patients during episodes of heightened discomfort.

“It provides support that helps ease the overall symptom burden.”


Quick Facts

Quick Fact: Managing Symptoms Related to Discomfort

This medication is commonly used across conditions presenting with acute episodes and provides short-term symptomatic assistance to help manage physical discomfort.

Regulatory References

  1. National Institutes of Health (NIH) MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Ceeta? (Ceftriaxone and Sulbactam)

Official regulatory documents define strict population eligibility rules for the use of Ceeta, primarily based on allergy status, age, and organ function.

Contraindicated Populations (Must Not Use)

Use of Ceeta is contraindicated in several specific populations, as defined by regulatory labeling:

  • Patients with documented hypersensitivity to Ceftriaxone, Sulbactam, any cephalosporin antibiotic, or any product excipient.
  • Individuals with a history of immediate and severe allergic reactions to penicillins or other beta-Lactam antibacterials due to the risk of cross-reactivity.
  • Neonates (up to 28 days old) who are receiving or are expected to receive intravenous calcium-containing solutions (e.g., parenteral nutrition), due to the risk of potentially fatal precipitation.
  • Hyperbilirubinemic neonates and premature infants up to 41 weeks postmenstrual age.

Restricted or Conditional Use

Population Group Regulatory Restriction or Condition
Combined Hepatic and Renal Dysfunction Dose of Ceftriaxone component must be limited to 2 grams daily (Restriction)
Pregnant Women Use is permitted only if clearly needed (Category B)
Lactating Women Use with caution is advised
Older Adults Generally permitted, provided renal and hepatic function are satisfactory

Standard labeled conditions generally permit use in adults and older adults without these specific contraindications or severe combined organ impairment. Age restrictions apply in the pediatric group, with use highly restricted or contraindicated in neonates.

What should I know about interactions with other medicines?

Ceeta's interaction profile is strictly defined by regulatory documentation, centering on the physical and chemical properties of its components. A critical constraint involves calcium-containing intravenous (IV) solutions. Co-administration is contraindicated in neonates (leq 28 days) due to the risk of ceftriaxone-calcium salt precipitation. In all other patients, the drug must never be mixed with calcium solutions, and sequential administration requires the IV lines to be thoroughly flushed with a compatible fluid between infusions.

A documented pharmacokinetic interaction occurs with Probenecid. This substance acts as a renal tubular secretion inhibitor, which leads to a reduction in the clearance of the Sulbactam component and an official increase in Sulbactam plasma concentrations.

Regarding pharmacodynamic effects, Ceftriaxone may adversely affect the efficacy of oral hormonal contraceptives. Furthermore, the drug may interact with agents that influence clotting, causing alterations in prothrombin time. This risk is noted to be greater in patient populations with impaired vitamin K stores, such as those with chronic hepatic impairment. Finally, the medicine must not be mixed with physically incompatible substances, including Vancomycin, Amsacrine, Aminoglycosides, and Fluconazole.

Mechanism of Action

How Ceeta Works

The mechanism of action for Ceeta is centered on the precise, targeted modulation of specific biological systems to influence defined physiological activity. The drug acts primarily by influencing core pathways, providing an action linked to its molecular function.

H2 Key Molecular Targets and Primary Action

Ceeta is characterized by its highly selective activity within domains involving receptor- or enzyme-mediated signaling. Its primary function is to bind to a distinct molecular target, which is responsible for initiating or transmitting signals within a key regulatory system. This binding is used to initiate or block specific signaling events, thereby modifying the immediate functional state of the receptor or enzyme system.

H2 Pathway Modulation and Signal Regulation

Following the primary molecular interaction, the drug’s effect cascades into central and/or peripheral signaling pathways. Ceeta engages mechanisms that regulate overactive or dysregulated processes by altering the activity flow driven by specific transmitters or mediators. This effect is relevant in systems where targeted pathway adjustment is required, modifying early molecular steps that shape systemic physiological outcomes.

H2 Modulating Physiological Responses

Ultimately, Ceeta’s mechanism serves to maintain a regulated state within targeted pathways. Through the attenuation of excessive signaling, the drug contributes to the modulation of overactive physiological responses and modifies the effects of excessive mediator activity. This precise mechanistic influence results in physiological adjustments consistent with the drug’s mechanism.

Dosage and Administration Information

How Ceeta is Used: Administration Guidelines

Ceeta (Ceftriaxone and Sulbactam) is a sterile powder for injection. Since it is a parenteral medicine, it must be prepared and given by a healthcare professional.

Approved Administration and Dosing

The medicine is given via the Intravenous (IV) route as an injection or infusion, or by Intramuscular (IM) injection.

Administration Detail Guideline (Ceftriaxone equivalent)
Standard Adult Daily Dose 1 g to 2 g per day
Maximum Daily Dose Up to 4 g of Ceftriaxone in total
Frequency Once daily (qDay) or in two equally divided doses (q12hr)
Typical Duration 4 to 14 days, continuing for 48 to 72 hours after fever resolves

Essential Preparation and Handling Instructions

  • Reconstitution: The powder must be dissolved in a specified sterile diluent immediately before use.
  • IV Administration Timing: When given intravenously, Ceeta should be administered as a slow IV injection over at least 5 minutes or, preferably, as an IV infusion lasting at least 30 minutes.
  • IM Dosing: For intramuscular use, doses exceeding 1 g of Ceftriaxone should be divided and injected into separate sites.
  • Incompatibility Restriction: The drug must not be mixed with or administered alongside calcium-containing IV solutions (e.g., Ringer's or Hartmann's solution).

Population-Specific Use

If a patient has combined kidney and liver impairment, the Ceftriaxone component dose should not exceed 2 g per day. Dose adjustments may also be necessary for the Sulbactam component in cases of marked renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ceeta

Ceeta (Ceftriaxone/Sulbactam) is a combination antibacterial medication that has been studied in clinical trials and other research settings to understand its evaluation in research contexts involving systemic bacterial infections. The research is primarily concerned with how the combination was studied alongside similar medicines and the patterns observed in patients with certain acute conditions.


Evidence for use in Complicated Urinary Tract Infections (cUTI)

The research base for Ceeta in clinical trials for complicated urinary tract infections (cUTI) involves Randomized Controlled Trials (RCTs). These studies were designed to study the Ceftriaxone/Sulbactam combination alongside other established antimicrobial treatments. Researchers designed these studies to examine composite favorable response, meaning they looked for how outcomes related to physical discomfort and symptoms evolved and evidence of bacterial clearance in the laboratory tests. Clinical reports described that the combination met pre-specified criteria when studied alongside certain other agents. However, these findings describe group patterns, not personal outcomes, and certainty remains low for outcomes beyond the immediate post-treatment period.


Evidence for use in Community-Acquired Pneumonia (CAP)

The research that has explored Ceeta in hospitalized patients with Community-Acquired Pneumonia (CAP) includes systematic reviews, meta-analyses, and observational studies. Studies focused on outcomes related to functional status and systemic imbalance, such as the rate of clinical assessment and patient survival in the short term. Studies monitored endpoints such as clinical response metrics and mortality figures, reporting patterns observed in the study populations when Ceeta was studied alongside other antimicrobial regimens. The research so far suggests patterns of symptom management in the acute setting but does not suggest certainty about long-term persistence.


Key Limitations and Uncertainty in the Evidence

While research has explored the evaluation of Ceeta across several types of acute infection, several research limitations and areas of uncertainty are noted. Follow-up durations were limited, focusing primarily on acute response rather than long-term health status. Evidence quality varies across studies, and subgroup findings are uncertain, as many trials were not specifically designed to detect differences in small patient groups. Data for children and adolescents are often insufficient.

Key Studies & References Evaluation of ceftriaxone-sulbactam-disodium edetate adjuvant combination against multi-drug resistant Gram-negative organisms

Frequently Asked Questions (FAQ)

Common questions about Ceeta (FAQ)


Q: What is the main reason doctors prescribe Ceeta?

Ceeta is an antibiotic prescribed to treat a wide variety of serious infections caused by susceptible bacteria. These approved uses, also called indications, can include infections of the lower respiratory tract, skin, urinary tract, bones, and joints. The specific infection being treated and the bacteria involved determine the necessity of the drug.


Q: Is Ceeta the same type of medicine as [similar drug name]?

Ceeta is a combination medicine consisting of two active ingredients. The main component, Ceftriaxone, belongs to the class of cephalosporin antibiotics. The second component, Sulbactam, is a beta-lactamase inhibitor that helps Ceftriaxone work against certain types of resistant bacteria.


Q: Is it common to feel tired when starting Ceeta?

Official documents list general symptoms such as 'unusual tiredness or weakness' under less common or rare side effects reported during use. Should a patient experience unexpected or severe fatigue, they are typically advised to discuss it with their prescribing healthcare professional.


Q: Can Ceeta affect my ability to drive?

Official product information notes that the main component of Ceeta has been associated with dizziness in some patients. This dizziness may potentially affect the ability to drive or operate complex machinery. Patients are generally informed that they should know how they react to the medication before engaging in activities that require full attention.


Q: Is Ceeta safe for older adults to use?

According to official information, studies have not identified overall differences in the safety or effectiveness of the drug between older and younger adults. Dose adjustments are generally not needed for older adults, provided their liver and kidney function are satisfactory.


Q: Are headaches a common side effect of Ceeta?

Headache is listed as an uncommon adverse reaction in the official prescribing information. Other commonly reported side effects typically involve the gastrointestinal system, such as diarrhea and loose stools.


Q: Is Ceeta a controlled substance?

Regulatory agencies, such as the U.S. DEA, classify the drug as having a schedule of 'None.' This classification indicates that the medicine is not considered a controlled substance.


Q: Is it safe to take over-the-counter pain relievers with Ceeta?

Official documentation notes potential interactions with various drug classes. Specifically, combining Ceftriaxone with certain non-steroidal anti-inflammatory drugs (NSAIDs) may increase the potential risk of adverse effects related to kidney function. Patients are generally advised to inform their healthcare provider of all other medications they are receiving.


Q: Is Ceeta approved for use in children?

Ceftriaxone is indicated for use in children and term neonates for appropriate conditions. However, it is officially contraindicated in premature neonates up to a specific post-menstrual age and in full-term neonates who have hyperbilirubinemia (jaundice) or are receiving intravenous calcium solutions.


Q: Why do some people stop taking Ceeta?

Official documents describe reasons for discontinuation based on safety and serious reactions. These reasons include a patient developing signs of a serious allergic reaction, gallbladder disease (pseudolithiasis), urolithiasis (kidney stones), or severe neurological adverse reactions. Discontinuation or changes to treatment are medical decisions typically made in consultation with a healthcare professional.


Q: Does Ceeta interact with alcohol?

One official source notes a possible disulfiram-like reaction with alcohol, though the potential for this specific effect is considered low. Patients are generally advised to discuss all substance use with their prescribing healthcare professional.


Q: Is there a generic version of Ceeta available?

Yes, the medication is available under its official generic names, Ceftriaxone and Sulbactam Injection. This combination is commonly marketed under various brand names depending on the manufacturer and the region.


Q: Are there long-term side effects associated with Ceeta use?

Official documents report risks associated with use, such as the formation of Ceftriaxone-calcium precipitates in the gallbladder (known as pseudolithiasis) and urinary tract (urolithiasis). These effects, which can sometimes look like stones on ultrasound, are often reversible after the medication is stopped.


Q: Can Ceeta make certain medical conditions worse?

Official information advises caution for use in patients with a history of certain gastrointestinal diseases, particularly colitis, or pre-existing severe liver or kidney impairment. The drug may potentially worsen these conditions, which is why official information highlights the need for physician monitoring.


Q: Is Ceeta used to treat any other conditions besides the main one?

Yes, official labels list multiple approved uses. These indications extend to various types of infections in the lower respiratory tract, skin, bones, joints, and certain sexually transmitted infections, in addition to the primary conditions it is prescribed for.


Q: Why is Ceeta sometimes prescribed for a long time?

While the usual duration of therapy is relatively short, from 4 to 14 days, official dosing guidelines permit longer courses. Certain severe or complicated infections, such as endocarditis or complicated bone infections, may require treatment for a longer period as determined by the physician.


Q: Can men and women take Ceeta for the same reasons?

Yes, the drug's approved indications are generally based on the type of infection or the specific pathogen being treated, and not on the sex of the patient. There are no sex-specific differences in the treatment rationale for the approved conditions.


Q: Is there any research about Ceeta being used in pregnancy?

Official labeling includes a Pregnancy Category for the drug. Regulatory sources state there are no adequate and well-controlled studies in pregnant women, and therefore, use is generally advised only if clearly needed.


Q: What is the primary function of Ceeta in the body?

Ceeta works by targeting and killing susceptible bacteria. The Ceftriaxone component achieves this by preventing bacteria from properly building their cell walls. The Sulbactam component protects the Ceftriaxone from being broken down by certain bacterial enzymes.


Q: Does taking Ceeta affect my sleep?

Neurological adverse reactions have been reported in official post-marketing surveillance, which can include somnolence (drowsiness) or lethargy. Such side effects are usually uncommon or rare, and patients are typically advised to report all unexpected reactions to their prescribing healthcare provider.


Q: What are the most common reasons a doctor would say 'no' to Ceeta?

The most common official reasons (contraindications) include a known allergy or hypersensitivity to cephalosporin or penicillin antibiotics. Additionally, it is contraindicated in neonates who have hyperbilirubinemia or require intravenous calcium solutions due to the risk of precipitation.


Q: Is it possible to be allergic to Ceeta?

Yes, serious, and occasionally fatal, hypersensitivity (allergic) reactions have been reported with the use of Ceftriaxone. A known history of allergy to cephalosporin or penicillin antibiotics is an official contraindication or serious warning.


Q: What does the FDA say about Ceeta?

The U.S. Food and Drug Administration (FDA) issues detailed prescribing information, also known as the official label, for Ceeta. This label outlines the drug's approved uses, appropriate dosing, contraindications, risks, and warnings.


Q: Are there different brand names for the medicine Ceeta?

The medicine is a combination of the two generic components, Ceftriaxone and Sulbactam, and is marketed globally under various brand names, depending on the manufacturer and the country where it is approved.


Q: Is Ceeta available as a liquid or only as a pill?

Official documents describe the medicine as a 'sterile powder for injection' or 'powder for solution for injection/infusion.' This means the medicine is given via a needle (IV or IM) by a healthcare professional, not taken orally as a pill or tablet.


Q: Why does the packaging say to read the guide before using Ceeta?

Patient counseling guides are required by regulatory agencies to ensure the user is informed about critical safety information and key warnings. This includes recognizing signs of serious allergic reactions, the risk of developing diarrhea, and the importance of adhering to the prescribed course of therapy.


Q: Can Ceeta cause stomach upset?

Yes, gastrointestinal adverse effects are common reactions noted in official documents. These often include loose stools, diarrhea, nausea, and vomiting.


Q: Does the effectiveness of Ceeta decrease over time?

Official information includes a warning about the Development of Drug-resistant Bacteria with prolonged or inappropriate use. This risk means that using the antibiotic when it is not needed can potentially lead to infections that are harder to treat.


Q: What are the main risks associated with taking Ceeta?

Major risks described in official warnings include the potential for serious hypersensitivity reactions, Clostridium difficile-associated diarrhea, and the formation of precipitates in the gallbladder or urinary tract. These risks necessitate careful monitoring by a healthcare professional.


Q: Are there different formulations of Ceeta?

Yes, the product is officially available as a powder that requires reconstitution. The resulting solution can then be administered via two approved routes: intravenous (IV) injection or infusion, or intramuscular (IM) injection.


Q: Why is it important to tell the doctor about all other medicines when starting Ceeta?

It is critical to disclose all other medicines and solutions to the doctor to assess the risk of dangerous drug-drug interactions. The most critical interaction is the potential for precipitation when mixed with calcium-containing intravenous solutions.

How should Ceeta be stored and disposed of?

Official Storage Requirements

Ceeta (Ceftriaxone and Sulbactam Powder for Injection) must be stored strictly according to its official labeling to maintain stability. The unopened vial should be stored below 30 C or 25 C and must be protected from both light and moisture. Regulatory documents explicitly state that the product must not be frozen.

Stability and Handling

Once the powder is mixed with solution, the resulting liquid is only stable for a limited time. For instance, the reconstituted solution should be used within 6 hours at room temperature or up to 24 hours if refrigerated (2 C to 8 C), after which it must be discarded. The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Ceeta must be carried out in accordance with local regulations for pharmaceutical waste. The product should not be thrown into household trash or poured into wastewater unless an approved government disposal method is followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ceeta found in:

A-Z Index: